THE PATH FORWARD: A ROADMAP FOR UNDERSTANDING AND INTEGRATING MULTI-CANCER EARLY DETECTION (MCED) IN PRIMARY CARE
Released On
May 24, 2024
Expires On
May 24, 2025
Media Type
Internet
Completion Time
75 minutes
Specialty
Education, Hematology-Oncology, Primary Care
Topic(s)
Bone Cancer, Brain Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Lung Cancer, Oncology, Prostate Cancer
This activity is provided by Purdue University College of Pharmacy, Simumetrix, and ArcheMedX.
This activity is supported in part by an independent education grant from the GRAIL.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The target audience for this curriculum are primary care physicians, internal medicine, and related health care professionals involved in screening patients for cancer. Healthcare professionals may be unfamiliar with the concept of patient-centered care models that provide optimal outcomes for screening patients for cancer. Physicians, Nurse Practitioners (NP), and Physician Assistants (PA) working in Primary Care and Family Medicine.
Program Overview
Managing cancer patients can be a challenge, especially if the patient is diagnosed in later stages. When managing these patients, how does your clinical practice compare to the experts? The Path Forward: A Roadmap for Understanding and Integrating Multi-Cancer Early Detection (MCED) in Primary Care has been developed to provide you with the needed education in the hopes of identifying cancer earlier ultimately improving patient outcomes and decreasing treatment costs. In a two-module series, Dr. Elizabeth O’Donnell will lead discussions that utilize augmented reality to provide critical information and tools that you can integrate into your daily practice – immediately impacting your patients by potentially identifying cancer earlier.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Explain the significance of Multi-Cancer Early Detection (MCED) as a complement to standard of care screening in the primary care setting, including its impact on patient outcomes and mortality rates.
- Analyze and compare traditional screening methods for cancer and how emerging MCED methods may complement those traditional methods, considering their respective strengths, limitations, and effectiveness.
- Evaluate the advantages and disadvantages of MCED, including cost-benefit considerations.
- Develop strategies and approaches to effectively integrate MCED into primary care settings, considering factors such as healthcare provider training, diagnostic pathways, addressing access barriers, and leveraging MCED to advance personalized medicine and patient-centered care.
Faculty
Elizabeth O'Donnell, MD
Dr. O’Donnell is a medical oncologist and the Director of the Multi-Cancer Early Detection Clinic in the Centers for Early Detection and Interception at the Dana-Farber Cancer Institute. She is an Assistant Professor of Medicine at Harvard Medical School and a physician-researcher in the Plasma Cell Disorder Center. She graduated from Vanderbilt Medical School and completed her residency at Beth Israel Deaconess Medical Center where she spent an additional year as a chief resident. She completed her fellowship in hematology and oncology at the Dana-Farber Cancer Institute. Her research focuses on early detection of cancer and therapeutic and lifestyle interventions for the treatment of plasma cell dyscrasias.
Catherine Marinac, PhD
Dr. Marinac is Assistant Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and Director of Population Sciences and Health Disparities Research in Dana-Farber’s Blood Cancer Prevention Program. She received a PhD in Public Health in 2016 from the University of California, San Diego with a degree emphasis in health behavior. Her research focuses on two key areas: (1) understanding the impact of energy balance factors on cancer susceptibility; and (2) cancer early detection.
Mylynda B. Massart, MD, PhD
Dr. Massart is a board-certified Family Medicine physician at UPMC, and associate professor at the University of Pittsburgh. She currently serves as the founder and Medical Director of the UPMC Primary Care Precision Medicine clinic and as the Associate Director of Clinical Services for the Institute for Precision Medicine. Dr. Massart is co-director of the HUB Core over Research Inclusivity and Community Partners Core at the Clinical and Translational Science Institute (CSTI). Her research interests are in developing education in genetics and precision medicine for primary care providers and trainees and being a research catalyst facilitating the inclusion of underrepresented populations in biomedical research. She teaches residents and medical students in her clinic and at the hospital and serves as medical director for Bethany Hospice. Currently, Dr. Massart is one of the co-investigators for the All of Us Pennsylvania research project working on community education and engagement. In addition, she is working as a co-investigator to create the local Discovery Biobank at the University of Pittsburgh and developing systems to return precision medicine results to providers and patients. Dr. Massart leads the Community Engagement Alliance Consultative Resource (CEACR), a partnership between the University of Pittsburgh CTSI and Community-Campus Partnerships for Health.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Simumetrix. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physician Credit Designation Statement
Purdue University College of Pharmacy designates this internet enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.
- FACULTY
- Elizabeth O'Donnell, MD
Honoraria/Travel: Exact Sciences
Steering Committee Member: Natera - Catherine Marinac, PhD
Scientific Advisor: Exact Sciences
Steering Committee Member: Natera
Research Funding: Grail - Mylynda B. Massart, MD, PhD
Speakers Bureau: Grail
- Elizabeth O'Donnell, MD
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Simumetrix staff, ArcheMedX staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for download upon completion of the activity.
Course Viewing Requirements
Supported Browsers (Desktop/Mobile)
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use:
Purdue University College of Pharmacy requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].